Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

X.-L. Xu, Y.-L. Yao, W.-Z. Xu, J.-G. Feng, W.-M. Mao
2015 Genetics and Molecular Research  
rs26279 (Ala1054Thr) and sensitivity to platinum-based chemotherapy (P = 0.014). A significant correlation was found between rs1105524 and progression-free survival (PFS), with the G/A and A/A genotypes (median survival time: 14.27 months; 95%CI = 9.80-18.75) suffering shorter survival than patients with the G/G genotype (median survival time: 26.37 months; 95%CI = 15.03-37.71) (P = 0.04). Our results showed that single nucleotide polymorphisms in MSH3 had an impact on the chemotherapy response
more » ... emotherapy response and prognosis of advanced NCSLC patients who were treated with platinum-based chemotherapy.
doi:10.4238/2015.april.15.16 pmid:25966119 fatcat:2fnce6jrzfc3nfu2ydqac5e7fy